South Korea: A recent study showed that lumbar sympathetic ganglion block with botulinum toxin type A increased foot temperature for 3 months in patients with complex regional pain syndrome, while also reducing pain.The study was published in the February 2022 issue of the journal Anesthesiology.
This study was designed to test the hypothesis that botulinum toxin prolongs the duration of lumbar sympathetic blockade as measured by sustained elevation of skin temperature.Jee Youn Moon and colleagues at Seoul National University Hospital in South Korea conducted a randomized, double-blind, controlled trial to examine the clinical outcomes of lumbar sympathetic ganglion block in patients with complex regional pain syndrome treated with botulinum toxin type A.
To do this, researchers performed lumbar sympathetic ganglion block in patients with complex regional pain syndrome of the lower extremity using 75 IU of botulinum toxin type A (botulinum toxin group) and a local anesthetic (control group).
The primary outcome was the change in relative temperature difference between the occluded sole and the contralateral sole at 1 month postoperatively.Changes in relative temperature difference and pain intensity over 3 months were secondary outcomes.
“We found that injection of botulinum toxin type A into the lumbar sympathetic ganglia increased the temperature of the affected foot at 3 months compared with local anesthetics,” the authors wrote. This was accompanied by reduced pain and improved cold tolerance.Also, it improves pain and numbness.”
Yongjae Yoo, Chang-Soon Lee, Jungsoo Kim, Dongwon Jo, Jee Youn Moon; Botulinum toxin type A for lumbar sympathetic ganglion block in complex regional pain syndrome: a randomized trial.
Medha Baranwal joined Medical Conversation in 2018 as Editor of Professional Medical Conversation.She covers multiple medical specialties including cardiac science, dentistry, diabetes and endoscopy, diagnostics, ENT, gastroenterology, neuroscience and radiology.
Post time: Mar-16-2022